NCT02793908 (PleyrisEndom) is a Phase 3 clinical trial of Pleyris in Endometriosis, sponsored by University Magna Graecia.

Who is sponsoring NCT02793908?

NCT02793908 is sponsored by University Magna Graecia.

What drugs are being tested in NCT02793908?

Interventions in NCT02793908: Pleyris, Crinone8.

What condition does NCT02793908 study?

NCT02793908 studies Endometriosis.

Is NCT02793908 still recruiting?

NCT02793908 is currently status unknown. Last updated 17 November 2016.

Last reviewed 2016-11-17 · How we verify

NCT02793908: PleyrisEndom

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Role of the Subcutaneous Progesterone in Luteal Phase Supplementation in Patients With Endometriosis

Status unknown Phase 3 Last updated 17 November 2016

What this trial tests

Phase 3 trial testing Pleyris in Endometriosis in 52 participants. Status unknown.

Timeline

1 June 2016

Primary endpoint
1 June 2017

1 August 2017

Quick facts

Lead sponsor	University Magna Graecia
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	52
Start date	1 June 2016
Primary completion	1 June 2017
Estimated completion	1 August 2017
Sites	1 location across Italy

Drugs / interventions tested

Pleyris — full drug profile →
Crinone8 — full drug profile →

Conditions studied

Endometriosis — all drugs for Endometriosis →

Sponsor

University Magna Graecia

Who can join

Adults 18 to 38, female only, with Endometriosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Delta VAS pain
Time frame: 7 days after the end of the menstrual period subsequent to the luteal supplementation
Patients will be asked to score their menstrual pain using a VAS scale

Sponsor's own description

The aim of the study protocol will be to compare the efficacy of subcutaneous progesterone (25 mg / day; Pleyris, IBSA Institut Biochimique SA) with vaginal progesterone (90 mg / day; Crinone, Merck Serono) administered during the luteal phase in term of pelvic pain reduction in patients with grade I-II endometriosis and / or endometrioma \<4 cm subjected to time intercourses or COS/IUI cycles.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure.
Reis FM, Coutinho LM, Vannuccini S, Batteux F, et al · · 2020 · cited 88× · PMID 32412587 · DOI 10.1093/humupd/dmaa009

Verify or expand the search:

Other recruiting trials for Endometriosis

Currently open trials in the same condition.

NCT06559852 — The Impact of Yoga on Endometriosis-Related Pain · NA · recruiting
NCT07393295 — Efficacy and Tolerability of TENS in Endometriosis-related Pain · NA · recruiting
NCT07134023 — Educational Program for the Multidisciplinary Support of Patients With Endometriosis · NA · recruiting
NCT07240883 — ENDO1000 - A UK-wide Endometriosis Research Project · recruiting
NCT06974773 — Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups · NA · recruiting

Other University Magna Graecia trials

Trials by the same sponsor.

NCT07173660 — Consensus Statements on Deep Brain Stimulation in Patients With Parkinson's Disease · not yet recruiting
NCT06830460 — Measurement of the Optic Nerve Diameter in Different Healthcare Operators · NA · not yet recruiting
NCT06274931 — Analysis of the Pulmonary Microbiome · unknown
NCT05398289 — FOUR-SIX TRIAL for the Treatment of Enterococcal Endocarditis · Phase 4 · not yet recruiting
NCT05681962 — Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02793908 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Magna Graecia
Last refreshed: 17 November 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02793908.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing